Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A sulfamyl diuretic. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose. (en)
|
http://linked.open.../drugbank/synonym
| - 3-Butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid (en)
- 3-Butylamino-4-phenoxy-5-sulfamoyl-benzoic acid (en)
- 3-Butylamino-4-phenoxy-5-sulfamoylbenzoic acid (en)
- Bumetanida (en)
- Bumetanidum (en)
- 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid (en)
|
http://linked.open...drugbank/toxicity
| - Overdosage can lead to acute profound water loss, volume and electrolyte depletion, dehydration, reduction of blood volume and circulatory collapse with a possibility of vascular thrombosis and embolism. Electrolyte depletion may be manifested by weakness, dizziness, mental confusion, anorexia, lethargy, vomiting and cramps. Treatment consists of replacement of fluid and electrolyte losses by careful monitoring of the urine and electrolyte output and serum electrolyte levels. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Take with food to reduce irritation. (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ynthesisReference
| - Felt, P.W.; US. Patent 3,634,583; January 11, 1972; assigned to Lovens Kemiske Fabrik Produktionsaktieselskab, Denmark. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Bumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| - * 0.2 - 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders] * 2.17 mL/min/kg [neonates receiving bumetanide for volume overload] * 1.8 +/- 0.3 mL/min/kg [geriatric subjects] * 2.9 +/- 0.2 mL/min/kg [younger subjects] (en)
|
http://linked.open...gbank/containedIn
| |